Cytek Biosciences, Inc. (CTKB) Market Cap & Valuation Ratios
Cytek Biosciences, Inc. (CTKB) has a market cap of $726.6M and a price-to-sales ratio of 3.5, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CTKBCytek Biosciences, Inc.Follow CTKB — free
—
Price chart with a free account
- Market cap
- 726.6M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Peers
medical devices · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| CTKB | 0.7 | — | 3.2 | — | -1.7% | +5% | -22% | -16% |
| SIBN | 1.0 | — | 4.5 | — | -0.5% | +15% | -8% | -10% |
| QDEL | 0.9 | — | 1.4 | — | — | -2% | -31% | -17% |
| IART | 0.9 | — | 1.5 | 10.8 | 9.3% | +0.8% | 4% | 2% |
| INMD | 0.9 | 9.8 | 1.3 | 5.8 | 9.5% | -6% | 23% | 19% |
| BBNX | 0.9 | — | 5.7 | — | -7.1% | +53% | -70% | -35% |
| AHCO | 0.8 | — | 0.8 | 9.0 | 11.9% | -0.4% | -4% | -4% |
| VREX | 0.8 | — | 1.2 | 10.3 | -2.6% | +5% | 8% | 8% |
| PACB | 0.7 | — | 6.7 | — | — | +2% | -84% | -22% |
| KIDS | 0.6 | — | 2.7 | — | -0.3% | +14% | -12% | -7% |
| TCMD | 0.5 | 21.9 | 1.3 | 11.2 | 5.0% | +17% | 10% | 15% |
| Median of these 10 | 15.8 | 1.4 | 10.3 | 2.4% | +4% | -6% | -6% |
; EV/Sales 3.2 vs. 1.4.
Growth vs. price
each dot a company · hover or tap for valuesCytek Biosciences, Inc. — questions
- What is Cytek Biosciences, Inc.'s market cap?
- $726.6M.
- What is Cytek Biosciences, Inc.'s price-to-sales ratio?
- 3.5.
Every figure on this page comes from Cytek Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.